Gift for Users!

Wed, 5 Dec 2007 01:12:52 +0100

Send a file to Perfusione.net DATABASE (you can send Pictures - Movies - Guidelines - Master Thesis - Power Points); you will receive at home a CD with all DATABASE for offline consultation and more extra files never published (including interesting full text articles)!

Send your files to: database@perfusione.net

Portable Life Support

Sat, 1 Dec 2007 22:47:17 +0100

Heparinless Ecmo

Sat, 1 Dec 2007 19:06:24 +0100

Brescia Hospital’s experience with Heparinless Ecmo in critical cases and in presence of massive and uncontrollable Haemorrage

2 Articoli:
Heparinless ECMO: a feasible and effective procedure for refractory pulmonary haemorrage or cardiopulmonary support for complex upperway respiratory interventions.
Heparinless ECMO for critical cases to provide cardiopulmonary support

Outcome after pediatric heart transplantation: two decades of a single center experience

Sat, 1 Dec 2007 17:05:33 +0100

Antonio Gambino a, Alessia Cerutti b, Giuseppe Feltrin a, Giuseppe Toscano a,
Giuseppe Tarantini c, Ornella Milanesi b, Annalisa Angelini d, Gino Gerosa a,*  a Department of Cardiovascular Surgery, University of Padova, Padova, Italy b Department of Pediatrics, University of Padova, Padova, Italy c Department of Cardiology, University of Padova, Padova, Italy d Department of Pathology, University of Padova, Padova, Italy
Received 26 June 2006; received in revised form 5 March 2007; accepted 6 March 2007.
* Corresponding author. Address: Istituto di Cardiochirurgia, Azienda Ospedaliera – Università degli Studi di Padova, Dipartimento di Scienze Cardiologiche, Toraciche, Vascolari, Sezione di Cardiochirurgia, Via Giustiniani, 2, 35128 Padova, Italy. Tel.: +39 0498212410; fax: +39 0498211895. (Email: gino.gerosa@unipd.it).
 Background: Twenty years after the first successful pediatric heart transplantation (HTx), the long-term outcome of this population is still unknown. Current study analyzes our results in pediatric HTx population. Methods and results: Between 1985 and 2005, we performed 604 HTx. Forty-three patients (7%) were less than 18-years old and six patients were less than 1-year old. Mean age at HTx was 9.7 ± 6.3 years (38 days–18 years). Indications were: cardiomyopathy in 33 patients (76%), congenital in 9 (21%), tumor in 1 (3%). Chronic immunosuppression was Cyclosporine A and Azathioprine-based. Overall survival at Kaplan–Meier analysis (CI 95%) was 82.5% at 1-year post-HTx, 73.5% at 5 years, 72.2% at 10 years, 62.1% at 15 years, and 49.3% at 20 years, respectively. We had 14 deaths (32%): 7 within the first year after HTx (early mortality, EM), 7 occurred later (late mortality, LM). Causes of EM were: graft failure (43%), acute rejection (43%) and post transplant lymphoproliferative disease (14%). Causes of LM were: neoplasms (57%), infection (28%), graft vasculopathy (15%). At late follow-up, cardiac function, somatic and psychoaffective development were normal. Fifteen patients (34%) developed neoplasms, nine patients (21%) hypertension, and three patients (8%) developed kidney dysfunction. Neoplasms were found to be an independent predictor of outcome (p = 0.039) (OR = 7). Conclusions: Overall survival in the pediatric population is better than adults’ population (62.1 vs 48% at 15 years after HTx). Neoplasms were the main comorbidities and causes of LM: at multivariate analysis, their incidence was related with hematic Cyclosporine A levels after 10 years from HTx (p = 0.01).
Source: Eur J Cardiothorac Surg 2007;32:220-224.

Echo by web!

Sat, 1 Dec 2007 12:44:33 +0100